Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
The Eliava Phage Therapy Center is a specialized medical facility located in Tbilisi, Georgia, dedicated to the clinical application of bacteriophages to treat antibiotic-resistant bacterial infections. It serves as the primary clinical outlet for the George Eliava Institute of Bacteriophages, Microbiology and Virology, which has been a global leader in phage research since its founding in 1923. The center provides personalized treatment protocols for patients suffering from complex infections in fields such as urology, dermatology, and pulmonology. Utilizing one of the world's largest collections of bacteriophages, the center offers both standardized pharmaceutical phage cocktails and custom-tailored autophage preparations. As global antibiotic resistance continues to rise, the Eliava Phage Therapy Center remains a critical international destination for patients seeking effective alternatives to traditional antimicrobial therapies.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Eliava Phage Therapy Center.